Hepatitis C News

Zepatier demonstrated high efficacy among patients with hepatitis C genotype 3, regardless of treatment experience or baseline resistance-associated substitutions, according to recently published data.

The high efficacy of direct-acting antivirals correlated with significant improvement in survival of patients who underwent liver transplantation for hepatitis C-related liver disease, according to a recently published study.

Model projections of scaled-up opioid substitution therapy and needle and syringe programs in Europe demonstrated a potential reduction in hepatitis C prevalence of 18% to 79% and could reduce treatment scale-up need by 20% to 80%.

Although hepatitis C cure rates continue to increase in the direct-acting antiviral era, especially in developed nations, some individuals still fail to achieve sustained virologic responses and others may have more risk factors for infection or transmission.

As direct-acting antiviral agents for hepatitis C virus become more accessible and affordable, there will be a greater need for primary care physicians to care for patients with HCV.

African-American patients were significantly less likely to achieve sustained virologic response after hepatitis C treatment with direct-acting antivirals compared with white patients, according to recently published data.

An international study showed that alcohol use disorder contributed significantly to liver disease burden in patients with hepatitis C. Researchers suggest that, where appropriate, countries develop strategies that combine direct-acting antiviral therapy with management of alcohol use disorders.

People who are homeless are more vulnerable to many infectious diseases than the general population and harder to reach for treatment.

Most patients with hepatitis C who were recent injection drug users achieved sustained virologic response after treatment with direct-acting antiviral Epclusa, according to recently published study results.

Hospitalization for hepatitis C increased significantly between 2005 and 2014, especially among baby boomers, men, African-American and Hispanic patients, and patients with mental health and substance abuse disorders, according to data from a Healthcare Cost and Utilization Project statistical brief.